Drug Discovery

#Cancer #Clinical trials #Drug development #Drug therapy

Experimental immunotherapy cancer treatment enters Phase II 

Australian clinical-stage drug development company Noxopharm has announced its DARRT-2 Phase II clinical trial has begun with patient enrollment in the US. It is said to have the potential to revolutionise cancer treatment by achieving cancer reduction without many of the unwanted side effects, cost limitations, and logistical challenges… Read More

#News

#Biotechnology #Drug development #Inflammatory Bowel Disease #Precision medicine

The start-up changing the game for IBD 

Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone #Trends & Analysis

#Bioproduction #Drug delivery #Drug development

How can the bioprocess industry respond to cost and maintain quality? 

Listen to this article on the DDW Podcast: Grant Cameron, Director at Clydeworth Consulting, examines the benefits of process intensification and highlights the steps which will improve process productivity, reduce environmental impact and decrease the cost of therapy manufacture while maintaining product quality.  The move to… Read More

#Business & Investment #Exclusive Content #Opinion

#Drug development #Drug discovery #Pharmaceuticals

Doloromics appoints President and Chief R&D Officer

Doloromics has appointed Dr. Chris Flores as their new President and Chief Research and Development Officer. In this role, Dr. Flores will be responsible for leading the Doloromics portfolio of drug discovery and development programmes, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators… Read More

#News

#Antibodies #Antibody libraries #Biologics #Biopharmaceuticals #DNA #Drug discovery #Drug targets #Screening

Newly launched antibody libraries put hard-to-drug targets within reach

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Collaboration #Drug discovery

This week in drug discovery (8-12 November) 

News round-up by DDW’s Megan Thomas for 8-12 November  DDW’s Megan Thomas has selected five stories which highlight the collaborative work being done across the drug discovery industry.  1. SAGA Diagnostics and AstraZeneca enter assay development agreement  SAGA Diagnostics, a cancer liquid… Read More

#News #Trending News

#Covid-19 #Drug design #Drug discovery #Immunology / Virology & Vaccines #Research #T-Cells

T-cell discovery could lead to new type of Covid-19 vaccines 

A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development.   In a study published in Nature, researchers found that individuals with potential exposure to… Read More

#Covid-19 #News #Trending News

#Biochemistry #Drug discovery #Drug targets #Mass spectrometry / NMR #Small molecules #Therapeutics

OMass unveils drug discovery pipeline for validated targets 

OMass Therapeutics has shared its pipeline of five novel, differentiated small molecule drug programmes, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs (G-protein-coupled receptors), solute carriers and intracellular protein complexes.  The company’s selected programmes focus on validated targets in immunology & rare disease indications with high unmet need. Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Funding

bit.bio receives $103 million for human cell production  

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. … Read More

#News

#Biology #Data #Drug discovery #Metabolomics #Precision medicine #Research

New metabolomics solution enables understanding of the microbiome 

Metabolon’s first offering from its SmartPanel portfolio aims to provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations.  “The metabolome offers a window into human… Read More

#Editor's Choice #News #Trending News

Seed funding
#Drug discovery #Research

Acquisition to create breakthrough approach for clinical trials 

THREAD has acquired Modus Outcomes to combine high-technology and high-science in one platform designed to achieve higher-quality outcomes for research sponsors.   As clinical trials have grown more complex, so has effectively designing and implementing endpoints, which are now required in most research studies. With this acquisition, THREAD… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Drug discovery

AI acquisition accelerates outcomes in early drug discovery 

X-Chem has announced the acquisition of Glamorous AI, combining X-Chem’s DNA-encoded library (DEL) data with the AI capabilities of Glamorous AI. This reportedly positions X-Chem as a leading service provider in machine learning-driven drug discovery.  “What AlphaFold did for protein folding, X-Chem and Glamorous AI will do for drug… Read More

#News

#Antibodies #Collaboration #Drug development #Drug discovery #Monoclonal antibodies

Nautilus and Abcam partner to accelerate proteome exploration  

Nautilus Biotechnology and Abcam have announced a strategic development and supply partnership to leverage Abcam’s recombinant monoclonal antibody development technologies and expertise to enhance Nautilus’ reagent research and development.   The partnership will initially focus on the collaborative development of affinity binding reagents for use on the… Read More

#News #Trending News

#Biotechnology #Case study #Drug discovery #High throughput screening

Case study: Discover an innovative CRO offering unique solutions

Drug discovery contract research organizations (CROs) offer an established infrastructure and experience that offers promising paths forward for various research projects. However, partnering with a CRO also presents key challenges, and companies should consider three questions: How long until data is delivered? Will the quality of the data instill confidence… Read More

#News

#Drug development #Neuroscience #Therapeutics

Appointment seeks to boost brain disorder therapy development 

Inscopix, a brain mapping platform, appointed David Gray as Chief Scientific Officer (CSO) in a new position to discover and develop more effective therapies for brain disorders.  Inscopix provides brain research tools to basic and translational researchers in academia as well as biotech and pharma companies in neuroscience. Read More

#News